세계의 오소바이오로직스 시장 규모는 2023년 70억 1,000만 달러로 평가되었고, 2031년 112억 4,000만 달러에 이를 전망이며, 예측기간인 2024년부터 2031년까지 CAGR 6.08%의 성장이 전망되고 있습니다. 시장은 주로 기술 개선에 의해 견인되고 있습니다. 생체재료와 수술방법의 개선 등 의료기술의 진보로 오소바이오로직스 솔루션을 보다 널리 이용할 수 있게 되었습니다. 뼈와 관절 문제를 더욱 효과적으로 치료할 수 있는 능력은 이러한 진보에 의해 가능해져서, 환자와 의사 모두에게 오소바이오로직스 옵션이 더욱 매력적이 되고 있습니다.
세계의 오소바이오로직스 시장은 세계의 노화로 확대되고 있습니다. 오랫동안 살아가는 사람들은 골다공증과 관절염과 같은 노화와 관련된 정형외과적 문제를 경험할 가능성이 높습니다. 노인들에게 널리 보이는 골절과 퇴행성 질환의 치유 과정을 촉진하기 위해 자주 이용되는 오소바이오로직스에 의한 치료에 대한 요구는 이 인구 역학의 변화에 의해 증가하고 있습니다.
세계의 오소바이오로직스 시장은 젊은층과 활동적인 사람들을 포함한 모든 연령층에서 정형외과적 문제가 증가하고 있기 때문에 성장하고 있습니다. 라이프 스타일 선택과 관련된 근골격계 문제와 스포츠 관련 상해 증가로 인해 오소바이오로직스 치료가 필요한 환자가 증가하고 있습니다.
게다가, 세계의 오소바이오로직스 시장의 역학은 보다 저침습성 수술 솔루션에 대한 요구 증가에 영향을 받고 있습니다. 오소바이오로직스는 저침습 수술에 자주 사용되며, 이는 회복 시간 단축, 감염 가능성의 감소, 수술 후 통증 감소 등의 이점이 있습니다. 오소바이오로직스는 보다 저침습 기술에 대한 전환으로, 수술, 특히 스포츠 의료의 외과수술에 보다 널리 사용되고 있습니다.
예를 들어, Tetrous, Inc.는 2023년 7월 스포츠 의료 수술에 사용되는 Enfix(TM) Demineralized Bone Fibre Implant의 미국 특허를 취득했다고 발표했습니다. EnFix 제품군의 최초 제품인 EnFix RC는 힘줄 수복술 전용으로 설계된 임플란트입니다. 현재 EnFix RC는 호주와 미국에서만 사용할 수 있습니다.
정형외과 질환의 급증이 시장을 뒷받침
세계 정형외과 질환 유병률이 증가함에 따라 세계의 오소바이오로직 시장은 급성장하고 있습니다. 골다공증, 관절염, 척추 질환 등의 증상을 경험하는 사람들이 증가하고 있으며, 효율적인 치료 솔루션에 대한 수요가 증가하고 있습니다. 뼈의 수리와 재생을 촉진하는 오소바이오로직스는 이러한 질병의 치료에 필수적입니다. 이러한 치료법의 필요성은 현대 라이프 스타일이 초래하는 근골격계 문제와 스포츠 부상 증가로 더욱 높아지고 있습니다. 시장은 건강에 대한 관심 증가를 위해 확대되고 있으며, 그 결과 다양한 정형외과적 문제에 대한 보다 정교하고 효과적인 솔루션을 창출하기 위한 연구개발이 추진되고 있습니다.
'The Lancet Rheumatology' 잡지에서 발표된 최근 연구에 따르면 향후 30년 동안 관절, 근육, 뼈 문제가 115% 증가할 전망입니다. 2050년까지 근육, 뼈, 관절, 인대, 힘줄, 척추 질환을 앓고 있는 사람들은 세계에서 10억 명이 넘을 것으로 보입니다. COVID-19 팬데믹의 영향은 이러한 예측에서 중요한 역할을 할 수 있습니다.
시장을 밀어주는 기술의 진보
기술의 진보는 특히 보다 효과적인 신제품 및 치료법의 형태로 세계의 오소바이오로직스 시장의 성장에 큰 역할을 하고 있습니다. 뼈와 관절 문제에 대한 치료는 생체 재료와 생물학적 요법의 발전으로 더욱 성공하기 쉽습니다. 예를 들어, 조직 공학과 재생 의학의 개선은 정형외과 수술에 필수적인 스캐 폴드와 뼈 이식의 질을 향상시켰습니다. 또한 3D 프린팅 기술의 발전으로 정형외과 기구 및 임플란트를 환자의 요구에 맞게 맞춤화할 수 있습니다. 환자의 결과를 개선할 뿐만 아니라, 이러한 기술의 진보로 치료할 수 있는 질병의 범위가 넓어지고, 세계의 오소바이오로직스 시장이 성장하고 있습니다.
이 보고서는 세계의 오소바이오로직스 시장에 대한 조사 분석을 통해 시장 규모 및 예측, 시장 역학, 주요 기업 상황 및 전망 등의 정보를 제공합니다.
Global orthobiologics market is projected to witness a CAGR of 6.08% during the forecast period 2024-2031, growing from USD 7.01 billion in 2023 to USD 11.24 billion in 2031. The global orthobiologics market is mostly driven by technological improvements. Orthobiologic solutions are now more widely available, thanks to advancements in medical technology, including improved biomaterials and surgical methods. The ability to treat bone and joint problems more effectively is being made possible by this advancement, which makes orthobiologic choices more appealing to patients and physicians alike.
The global orthobiologics market is expanding due to the ageing of the world's population. People who live longer are more likely to experience age-related orthopedic problems like osteoporosis and arthritis. The need for orthobiologic therapies, which are frequently utilized to accelerate the healing process for fractures and degenerative diseases that are widespread among the elderly, is increased by this shift in demography.
The global orthobiologics market is growing due to an increase in orthopedic problems across all age categories, including younger and more active people. An increasing number of patients require orthobiologic therapy due to the rise in musculoskeletal problems and sports-related injuries linked to lifestyle choices.
Furthermore, the dynamics of the global orthobiologics market is influenced by the growing desire for less intrusive surgical solutions. Orthobiologics are frequently utilized in minimally invasive operations; its benefits include shortened recovery times, a lower chance of infection, and decreased postoperative pain. Orthobiologic products are being more widely used in operations, particularly sports medicine surgical procedures, because of the shift towards less intrusive techniques.
Tetrous, Inc., for example, announced in July 2023 the issuance of a U.S. patent for Enfix(TM) Demineralized Bone Fibre Implants for use in sports medicine surgical operations. The first product in the EnFix family, EnFix RC, is an implant designed specifically for rotator cuff repair procedures. Australia and the United States are the only countries where it is now accessible.
Surge in Orthopedic Disorders Boosting the Market
The global orthobiologics market is growing rapidly due to the rising prevalence of orthopedic disorders worldwide. More people are experiencing conditions, including osteoporosis, arthritis, and spinal problems, which increases the demand for efficient treatment solutions. By encouraging bone repair and regeneration, orthobiologics is critical in treating these conditions. The need for these therapies is further increased by the rise in musculoskeletal issues and sports injuries brought on by contemporary lifestyles. The global orthobiologics market is expanding because of the rise in health concerns, which, in turn, is driving research and development efforts to produce more sophisticated and efficacious solutions for various orthopedic problems.
According to a recent study published in 'The Lancet Rheumatology' journal, there will be a 115 percent increase in problems of the joints, muscles, and bones during the next thirty years. By 2050, more than a billion people worldwide will likely be suffering from illnesses of the muscles, bones, joints, ligaments, tendons, and spine-a number that has increased from roughly half a billion in 2020. The impact of the Covid pandemic on our musculoskeletal system may play a significant role in these predictions.
Technological Advancements Fueling the Market
Technological advancements play a major role in the growth of the global orthobiologics market, particularly in the form of new and more effective products and treatment methods. Treatments for problems with the bones and joints are now more successful because of developments in biomaterials and biological therapies. For instance, improvements in tissue engineering and regenerative medicine have raised the calibre of scaffolds and bone transplants that are essential for orthopedic procedures. Advances in 3D printing technology also allow for customized orthopedic devices and implants, made to fit each patient's unique needs. In addition to improving patient outcomes, these technological advancements broaden the range of illnesses that can be treated, which grows the global orthobiologics market.
For instance, leading medical technology business, Xenco Medical showcased its TrabeculeX Continuum at the 2024 Consumer Electronics Show in Las Vegas, Nevada, on January 11th, showing its convergent technology that bridges biomaterials and digital health. The TrabeculeX Continuum, which integrates the TrabeculeX Bioactive Matrix and the TrabeculeX Recovery App, is the first technologically enabled link between digital health and orthobiologics, streamlining a patient's postoperative course and biomaterial implantation.
Growing Demand for Orthobiologics in Spinal Fusion Surgeries
Orthopedics use in spinal fusion procedures is a major driver of the global orthobiologics market. In joining two or more spinal vertebrae, orthobiologic materials, such as demineralized bone matrices, bone transplants, and bone morphogenetic proteins, play a critical role in spinal fusion. They lead to better patient outcomes and healing by dramatically improving the bone development and healing required for a successful fusion. The number of spinal fusion operations rises because of the rising incidence of spinal diseases, which are linked to factors including an aging population and unproductive lifestyles. The increase in surgeries is driving the demand for orthobiologic products, which, in turn, is propelling the growth and development of the global orthobiologics market.
For example, the UK-based orthobiologics company Locate Bio announced in May 2023 that LDGraft had received a breakthrough product classification from the US Food and Drug Administration (FDA). LDGraft is developed for anterior lumbar interbody spinal fusion (ALIF) procedures conducted at one level, from L3 to S1, for patients with degenerative disc disease.
The Growing Popularity of Demineralized Bone Matrix
The global orthobiologics market is growing due to the escalating demand for demineralized bone matrix (DBM). DBM is becoming increasingly well-liked because it works well for various orthopedic procedures, including spinal fusion, bone fractures, and joint reconstructions. DBM is a processed type of allograft bone that keeps growth factors essential for bone regeneration. DBM is becoming more popular due to its ability to stimulate bone growth and to work well with other grafts to enhance results. Thus, the growing demand for DBM in orthopedic surgeries is a major driver for the growth of the global orthobiologics market and illustrates the changing landscape of surgical bone healing techniques.
For instance, the full market release and initial implant of Legacy Demineralized Bone Matrix (DBM), a putty for repairing spaces or gaps in bony defects or traumatic injuries of the spine, pelvis, or extremities, were announced in October 2022 by Orthofix Medical Inc., a multinational medical device company with a focus on spine and orthopedics.
North America Dominates the Market
Numerous important variables are responsible for North America's dominant position in the global orthobiologics market. The area is home to a state-of-the-art healthcare system that stimulates substantial medical research and development, particularly in orthopedics. When combined with a significant investment in healthcare and a dedication to innovation, these features improve its position in the market. Orthobiologic treatments are highly needed due to the high prevalence of orthopedic disorders in North America, which are caused by an ageing population, increasing obesity rates, and lifestyle-related musculoskeletal problems. The strict regulatory environment in the area also guarantees the supply of safe and high-quality orthobiologic products, which propels the growth of the global orthobiologics market.
For example, in August 2022, CGBio, a firm that develops novel synthetic bone grafts, and Orthofix Medical Inc., a multinational medical device company focused on spine and orthopedics, signed a strategic cooperation arrangement. The two businesses collaborated to develop Novosis's recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials. They also aim to create other tissue regenerative solutions for the American and Canadian markets.
Future Market Scenario (2024 - 2031F)
The global orthobiologics market is poised for growth, influenced by the aging global population, a rise in orthopedic conditions, and breakthroughs in orthobiologic technologies.
The future of the global orthobiologics market is expected to be shaped by continuous research and development efforts, paving the way for the introduction of innovative and more efficient orthobiologic solutions, including cutting-edge biomaterials and regenerative medicine.
With the improvement of healthcare systems in emerging countries, the adoption of orthobiologic treatments in these areas is expected to rise, significantly contributing to the market's expansion.
Potential changes in government regulations and health insurance reimbursement policies could significantly influence the market, impacting the usage and accessibility of orthobiologic treatments and products.
Key Players Landscape and Outlook
One of the key factors driving the growth of the global orthobiologics market is the current noteworthy rise in mergers and acquisitions (M&A). Larger organisations are acquiring smaller or equivalent businesses through M&A transactions in order to expand their product offerings, break into new markets, and gain access to cutting-edge research and technology. Companies can increase their competitive edge, boost market presence, and achieve cost efficiency through these strategic consolidations. Furthermore, the combination of information and resources encourages creativity, which produces better orthobiologic products. Therefore, M&A activity plays a crucial role in shaping the market environment and promoting a more diverse and technologically advanced orthobiologics industry.
For example, in November 2023, Berkeley Biologics-a fully owned subsidiary of GNI Group-completed the acquisition of Elutia's Orthobiologics business unit for up to $35 million in cash. At closing, Elutia received a $15 million upfront payment, with additional earnout payments of up to $20 million possible over the next five years. Through the acquisition, Elutia hopes to give doctors access to the potency of targeted therapies, along with the advantages of natural biological materials for wound healing.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.